KOMIPHARM INTERNATIONAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,115 KRW | -.--% |
|
-4.08% | -1.79% |
| 05-29 | Komipharm International Co., Ltd. announces an Equity Buyback for 481,927 shares. | CI |
| 05-29 | Komipharm International Co., Ltd. authorizes a Buyback Plan. | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,172,660 | 969,689 | 858,749 | 548,450 | 446,056 | 293,942 |
| Enterprise Value (EV) 1 | 1,186,544 | 989,663 | 877,311 | 567,943 | 473,383 | 324,224 |
| P/E ratio | -78 x | -45.4 x | -305 x | -123 x | -68.5 x | -73.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 33.5 x | 27.3 x | 23.1 x | 15.3 x | 11.2 x | 6.89 x |
| EV / Revenue | 33.9 x | 27.9 x | 23.6 x | 15.8 x | 11.9 x | 7.6 x |
| EV / EBITDA | -447 x | -628 x | 561 x | -332 x | 21,189 x | -118 x |
| EV / FCF | -180 x | -159 x | -559 x | -197 x | -147 x | -162 x |
| FCF Yield | -0.56% | -0.63% | -0.18% | -0.51% | -0.68% | -0.62% |
| Price to Book | 12 x | 13.2 x | 11.3 x | 8.25 x | 7.34 x | 5.22 x |
| Nbr of stocks (in thousands) | 69,941 | 69,989 | 70,276 | 70,276 | 70,239 | 70,153 |
| Reference price 2 | 16,766 | 13,855 | 12,220 | 7,804 | 6,351 | 4,190 |
| Announcement Date | 19-03-19 | 20-03-17 | 21-03-17 | 22-03-16 | 23-03-15 | 24-03-20 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 34,994 | 35,490 | 37,160 | 35,847 | 39,801 | 42,647 |
| EBITDA 1 | -2,653 | -1,576 | 1,565 | -1,708 | 22.34 | -2,744 |
| EBIT 1 | -6,214 | -5,434 | -2,175 | -5,291 | -3,804 | -6,273 |
| Operating Margin | -17.76% | -15.31% | -5.85% | -14.76% | -9.56% | -14.71% |
| Earnings before Tax (EBT) 1 | -19,059 | -13,851 | -3,957 | -5,934 | -7,480 | -5,739 |
| Net income 1 | -14,303 | -21,363 | -2,816 | -4,459 | -6,514 | -3,979 |
| Net margin | -40.87% | -60.2% | -7.58% | -12.44% | -16.37% | -9.33% |
| EPS 2 | -214.9 | -305.5 | -40.10 | -63.64 | -92.73 | -57.00 |
| Free Cash Flow 1 | -6,609 | -6,207 | -1,569 | -2,886 | -3,218 | -2,004 |
| FCF margin | -18.89% | -17.49% | -4.22% | -8.05% | -8.09% | -4.7% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19-03-19 | 20-03-17 | 21-03-17 | 22-03-16 | 23-03-15 | 24-03-20 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 13,884 | 19,975 | 18,563 | 19,493 | 27,327 | 30,282 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -5.233 x | -12.67 x | 11.86 x | -11.41 x | 1,223 x | -11.04 x |
| Free Cash Flow 1 | -6,609 | -6,207 | -1,569 | -2,886 | -3,218 | -2,004 |
| ROE (net income / shareholders' equity) | -15.1% | -26.7% | -5.13% | -7.89% | -10.8% | -9.41% |
| ROA (Net income/ Total Assets) | -2.69% | -2.56% | -1.1% | -2.79% | -2.09% | -3.4% |
| Assets 1 | 532,531 | 835,120 | 256,407 | 159,925 | 311,010 | 116,891 |
| Book Value Per Share 2 | 1,402 | 1,047 | 1,085 | 946.0 | 865.0 | 803.0 |
| Cash Flow per Share 2 | 288.0 | 270.0 | 214.0 | 171.0 | 154.0 | 211.0 |
| Capex 1 | 5,434 | 5,740 | 1,656 | 813 | 848 | 637 |
| Capex / Sales | 15.53% | 16.17% | 4.46% | 2.27% | 2.13% | 1.49% |
| Announcement Date | 19-03-19 | 20-03-17 | 21-03-17 | 22-03-16 | 23-03-15 | 24-03-20 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -1.79% | 208M | |
| +18.66% | 8.74B | |
| +23.75% | 3.67B | |
| -0.42% | 3.25B | |
| +18.07% | 1.73B | |
| -16.99% | 1.38B | |
| -0.39% | 1.31B | |
| -26.05% | 1.24B | |
| -17.86% | 1.07B | |
| -6.77% | 976M |
- Stock Market
- Equities
- A041960 Stock
- Financials Komipharm International Co., Ltd.
